# Analyzing the Pharmacodynamic Substances and the Effects of Xingnaojing for Mild-to-Severe Acute Ischemic Stroke

> **NCT05559307** · PHASE4 · UNKNOWN · sponsor: **Ying Gao** · enrollment: 20 (estimated)

## Conditions studied

- Ischemic Stroke, Acute

## Interventions

- **DRUG:** Xingnaojing injection

## Key facts

- **NCT ID:** NCT05559307
- **Lead sponsor:** Ying Gao
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-16
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05559307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05559307, "Analyzing the Pharmacodynamic Substances and the Effects of Xingnaojing for Mild-to-Severe Acute Ischemic Stroke". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05559307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*